Trevi Therapeutics
$19.07
26
+$1.71+9.85% Friday 20:00
+$0.04+0.21%Friday 23:30After hours
Statistics
Day High
19.11
Day Low
19
52W High
20.15
52W Low
6.55
Volume
270,937
Avg. Volume
-
Mkt Cap
2.71B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.13
-0.11
-0.09
-0.08
Expected EPS
-0.106682
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-42.76MNet Income
Analyst Ratings
21.00Average Price Target
The highest estimate is 24.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow TRVI. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Biogen
BIIB
Mkt Cap29.4B
Alkermes
ALKS
Mkt Cap8.66B
Acadia Pharmaceuticals
ACAD
Mkt Cap4.49B
AMGEN
AMGN
Mkt Cap196.12B
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.37B
Jazz Pharmaceuticals
JAZZ
Mkt Cap15.32B
Novartis
NVS
Mkt Cap293.94B
Abbvie
ABBV
Mkt Cap438.31B
About
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Show more...
CEO
Ms. Jennifer L. Good
Employees
34
Country
United States
ISIN
US89532M1018
Listings
0 Comments
Share your thoughts
FAQ
What is Trevi Therapeutics stock price today?▼
The current price of TRVI is $19.07 USD — it has increased by +9.85% in the past 24 hours. Watch Trevi Therapeutics stock price performance more closely on the chart.
What is Trevi Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Trevi Therapeutics stocks are traded under the ticker TRVI.
Is Trevi Therapeutics stock price growing?▼
TRVI stock has risen by +6.89% compared to the previous week, the month change is a +10.81% rise, over the last year Trevi Therapeutics has showed a +177.99% increase.
What is Trevi Therapeutics market cap?▼
Today Trevi Therapeutics has the market capitalization of 2.71B
When is the next Trevi Therapeutics earnings date?▼
Trevi Therapeutics is going to release the next earnings report on August 06, 2026.
What were Trevi Therapeutics earnings last quarter?▼
TRVI earnings for the last quarter are -0.09 USD per share, whereas the estimation was -0.08 USD resulting in a -18.96% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Trevi Therapeutics revenue for the last year?▼
Trevi Therapeutics revenue for the last year amounts to 0 USD.
What is Trevi Therapeutics net income for the last year?▼
TRVI net income for the last year is -42.76M USD.
How many employees does Trevi Therapeutics have?▼
As of July 19, 2026, the company has 34 employees.
In which sector is Trevi Therapeutics located?▼
Trevi Therapeutics operates in the Health & Wellness sector.
When did Trevi Therapeutics complete a stock split?▼
Trevi Therapeutics has not had any recent stock splits.
Where is Trevi Therapeutics headquartered?▼
Trevi Therapeutics is headquartered in New Haven, United States.